{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:26Z","timestamp":1792601126582,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.eclinm.2022.101718","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T21:42:36Z","timestamp":1668202956000},"page":"101718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: a retrospective cohort study"],"prefix":"10.1016","volume":"55","author":[{"given":"Elizabeth","family":"Vera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Grajkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Briceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja K.","family":"Crandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Leeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-8188","authenticated-orcid":false,"given":"Jason","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-6699","authenticated-orcid":false,"given":"Jennifer","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina A.","family":"Acquaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-8139","authenticated-orcid":false,"given":"Varna","family":"Jammula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Boris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Polskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Penas-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Theeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri S.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito R.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2022.101718_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/neuonc\/nov166","article-title":"The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101718_bib2","first-page":"2","article-title":"Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials","volume":"2","author":"Dirven","year":"2015","journal-title":"Neurooncol Pract"},{"issue":"14","key":"10.1016\/j.eclinm.2022.101718_bib3","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.ejca.2014.06.016","article-title":"The level of patient-reported outcome reporting in randomized controlled trials of brain tumour patients: a systematic review","volume":"50","author":"Dirven","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101718_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju129","article-title":"Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials","volume":"106","author":"Reeve","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101718_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2015.0530","article-title":"Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient","volume":"1","author":"Basch","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101718_bib6","first-page":"4","article-title":"Clinical outcome assessments in neuro-oncology: a regulatory perspective","volume":"3","author":"Sul","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101718_bib7","first-page":"81","article-title":"Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials","volume":"6","author":"Molinari","year":"2019","journal-title":"Neurooncol Pract"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101718_bib8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials; the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101718_bib9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","article-title":"ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research","volume":"22","author":"Reeve","year":"2013","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101718_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101718_bib11","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomized controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2022.101718_bib13","series-title":"BEST. (Biomarkers, EndpointS, and other Tools) resource","year":"2016"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101718_bib14","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(18)30004-4","article-title":"Working plan for the use of patient-reported outcome measures in adults with brain tumors: a response assessment in neuro-oncology (RANO) initiative","volume":"19","author":"Dirven","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101718_bib15","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S1470-2045(19)30796-X","article-title":"Glioma patient-reported outcome assessment in clinical care and research: a response assessment in neuro-oncology collaborative report","volume":"21","author":"Armstrong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101718_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-006-9135-z","article-title":"Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)","volume":"80","author":"Armstrong","year":"2006","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101718_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101718_bib18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2022.101718_bib19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/j.pain.0000000000000890","article-title":"Determination of mild, moderate, and severe pain interference in patients with cancer","volume":"158","author":"Shi","year":"2017","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101718_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"16","author":"Group","year":"1990","journal-title":"Health Policy"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101718_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.eclinm.2022.101718_bib22","series-title":"Evaluation of chemotherapeutic agents","first-page":"191","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","author":"Karnofsky","year":"1949"},{"issue":"14","key":"10.1016\/j.eclinm.2022.101718_bib23","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1002\/cncr.25892","article-title":"The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients","volume":"117","author":"Armstrong","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2022.101718_bib24","first-page":"329","article-title":"Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors","volume":"47","author":"Levin","year":"1977","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101718_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02295996","article-title":"Note on the sampling error of the difference between correlated proportions or percentages","volume":"12","author":"McNemer","year":"1947","journal-title":"Psychometrika"},{"key":"10.1016\/j.eclinm.2022.101718_bib26","series-title":"IBM SPSS statistics for windows, version 26.0","author":"IBM Corp","year":"2019"},{"key":"10.1016\/j.eclinm.2022.101718_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022004485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022004485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:08:17Z","timestamp":1770152897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022004485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":26,"alternative-id":["S2589537022004485"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101718","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101718"}}